NAUTILUS BIOTECHNOLOGY INC's ticker is NAUT and the CUSIP is 63909J108. A total of 74 filers reported holding NAUTILUS BIOTECHNOLOGY INC in Q1 2024. The put-call ratio across all filers is 0.13 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,489,485 | -18.3% | 636,532 | +2.7% | 0.11% | -15.9% |
| Q1 2024 | $1,822,421 | +2.0% | 619,871 | +3.7% | 0.13% | -14.9% |
| Q4 2023 | $1,787,329 | -5.4% | 597,769 | 0.0% | 0.15% | -17.8% |
| Q3 2023 | $1,888,950 | -18.4% | 597,769 | -0.0% | 0.18% | +0.6% |
| Q2 2023 | $2,314,152 | +39.7% | 597,972 | 0.0% | 0.18% | +27.0% |
| Q1 2023 | $1,656,382 | +156606.0% | 597,972 | +1.8% | 0.14% | +48.4% |
| Q4 2022 | $1,057 | -99.9% | 587,305 | +16.4% | 0.10% | -11.2% |
| Q3 2022 | $1,069,000 | -21.2% | 504,404 | 0.0% | 0.11% | -20.7% |
| Q2 2022 | $1,357,000 | -38.6% | 504,404 | +18.1% | 0.14% | -22.9% |
| Q1 2022 | $2,211,000 | 0.0% | 426,924 | 0.0% | 0.18% | 0.0% |
| Q4 2021 | $2,211,000 | +1874.1% | 426,924 | +2237.9% | 0.18% | +1650.0% |
| Q3 2021 | $112,000 | – | 18,261 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AH Equity Partners Bio II, L.L.C. | 16,298,006 | $70,733,000 | 40.75% |
| Madrona Venture Group, LLC | 6,020,770 | $26,130,000 | 7.74% |
| AH Equity Partners LSV II, L.L.C. | 1,355,911 | $5,885,000 | 4.24% |
| Ally Bridge Group (NY) LLC | 1,080,566 | $4,690,000 | 3.48% |
| ArchPoint Investors | 1,449,551 | $6,291,000 | 2.17% |
| Tikvah Management LLC | 1,488,895 | $6,462,000 | 2.07% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $8,680,000 | 0.84% |
| Perceptive Advisors | 9,111,151 | $39,542,000 | 0.79% |
| SPHERA FUNDS MANAGEMENT LTD. | 840,000 | $3,646,000 | 0.52% |
| Decheng Capital Management III (Cayman), LLC | 300,000 | $1,302,000 | 0.40% |